Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
Public ClinicalTrials.gov record NCT05254171. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma
Study identification
- NCT ID
- NCT05254171
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- Panbela Therapeutics, Inc.
- Industry
- Enrollment
- 600 participants
Conditions and interventions
Interventions
- Gemcitabine Drug
- Nab-paclitaxel Drug
- Placebo Other
- SBP-101 Drug
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 7, 2022
- Primary completion
- Aug 28, 2026
- Completion
- Dec 31, 2026
- Last update posted
- Nov 5, 2024
2022 – 2027
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Genesis Cancer and Blood Institute (SCRI) | Hot Springs | Arkansas | 71913 | Withdrawn |
| Providence Medical Foundation | Fullerton | California | 92835 | Recruiting |
| Yale Cancer Center | New Haven | Connecticut | 06519 | Recruiting |
| MedStar Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | Active, not recruiting |
| Henry Ford Health System | Detroit | Michigan | 48202-2643 | Recruiting |
| CentraCare Health | Saint Cloud | Minnesota | 56303 | Withdrawn |
| Columbia University Medical Center | New York | New York | 10032 | Recruiting |
| University of Rochester | Rochester | New York | 14642 | Recruiting |
| Mark H Zangmeister Center - SCRI - PPDS | Columbus | Ohio | 43219 | Terminated |
| Tennessee Oncology NASH - SCRI - PPDS | Nashville | Tennessee | 37203 | Active, not recruiting |
| HOPE Cancer Center of East Texas | Tyler | Texas | 75701 | Recruiting |
| Medical Oncology Associates - Spokane | Spokane | Washington | 99208 | Recruiting |
| MultiCare Regional Cancer Center - Tacoma | Tacoma | Washington | 98405 | Recruiting |
| Froedtert Hospital & the Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 78 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05254171, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 5, 2024 · Synced Apr 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05254171 live on ClinicalTrials.gov.